93 related articles for article (PubMed ID: 9654158)
1. Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia.
Tajima F; Kawatani T; Ishiga K; Nanba E; Kawasaki H
Eur J Haematol; 1998 May; 60(5):289-96. PubMed ID: 9654158
[TBL] [Abstract][Full Text] [Related]
2. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
3. Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages.
Willman CL; Stewart CC; Longacre TL; Head DR; Habbersett R; Ziegler SF; Perlmutter RM
Blood; 1991 Feb; 77(4):726-34. PubMed ID: 1825181
[TBL] [Abstract][Full Text] [Related]
4. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
5. Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders.
Kawakita M; Yonemura Y; Miyake H; Ohkubo T; Asou N; Hayakawa K; Nakamura M; Kitoh T; Osawa H; Takatsuki K
Br J Haematol; 1995 Sep; 91(1):23-9. PubMed ID: 7577639
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia.
Cole SR; Aylett GW; Harvey NL; Cambareri AC; Ashman LK
Leukemia; 1996 Feb; 10(2):288-96. PubMed ID: 8637238
[TBL] [Abstract][Full Text] [Related]
7. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.
Hirano T; Yoshikawa R; Harada H; Harada Y; Ishida A; Yamazaki T
Mol Cancer; 2015 Apr; 14():90. PubMed ID: 25928165
[TBL] [Abstract][Full Text] [Related]
10. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression.
Reuss-Borst MA; Bühring HJ; Schmidt H; Müller CA
Leukemia; 1994 Feb; 8(2):258-63. PubMed ID: 7508533
[TBL] [Abstract][Full Text] [Related]
11. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
12. Use of myeloperoxidase mRNA as a marker for myeloid lineage in acute leukemias.
Crisan D; David D; DiCarlo R
Arch Pathol Lab Med; 1996 Sep; 120(9):828-34. PubMed ID: 9140287
[TBL] [Abstract][Full Text] [Related]
13. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Schwartz S; Heinecke A; Zimmermann M; Creutzig U; Schoch C; Harbott J; Fonatsch C; Löffler H; Büchner T; Ludwig WD; Thiel E
Leuk Lymphoma; 1999 Jun; 34(1-2):85-94. PubMed ID: 10350335
[TBL] [Abstract][Full Text] [Related]
14. Preferential release of high amounts of interleukin-8 by myeloid blasts showing monocytic differentiation.
Vinante F; Rigo A; Tecchio C; Patuzzo C; Ricetti MM; Morosato L; Cassatella MA; Chilosi M; Pizzolo G
Haematologica; 1996; 81(3):195-200. PubMed ID: 8767523
[TBL] [Abstract][Full Text] [Related]
15. Auer rods in mature granulocytes: a unique morphologic feature of acute myelogenous leukemia with maturation.
Stass SA; Lanham GR; Butler D; Williams DL; Peiper SC; Kalwinsky DK; Dahl GV
Am J Clin Pathol; 1984 May; 81(5):662-5. PubMed ID: 6586071
[TBL] [Abstract][Full Text] [Related]
16. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
17. Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia.
Lauria F; Bagnara GP; Rondelli D; Raspadori D; Strippoli P; Bonsi L; Ventura MA; Montanaro LL; Bubola G; Tura S
Leuk Lymphoma; 1995 Aug; 18(5-6):451-5. PubMed ID: 8528052
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the RET gene in human acute myeloid leukemia.
Gattei V; Degan M; Aldinucci D; De Iuliis A; Rossi FM; Mazzocco FT; Rupolo M; Zagonel V; Pinto A
Ann Hematol; 1998 Nov; 77(5):207-10. PubMed ID: 9858145
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
20. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
